Kojic acid is legally permitted as a cosmetic ingredient in the United States under FDA jurisdiction, where it is considered a cosmetic (not a drug) as long as no drug claims are made. The FDA does not pre-approve cosmetic formulas, so kojic acid body lotions can be sold in the US without regulatory pre-clearance, provided the product is properly labeled with an accurate INCI ingredient list and no claims are made suggesting it treats, prevents, or cures a disease or skin condition.
In the European Union, the situation is more nuanced. Kojic acid was evaluated by the EU's Scientific Committee on Consumer Safety (SCCS). The SCCS issued an opinion that kojic acid is safe for use in face products at concentrations up to 1% and body products at up to 1% as well, under the condition that the product does not result in systemic exposure exceeding a certain threshold. As of the current regulatory landscape, kojic acid is permitted in EU cosmetics at these concentrations, but it is on the watch list for further restriction, so formulators targeting the EU market keep concentrations at or below 1% in leave-on products to stay well inside safety margins. Products sold into the EU also require a full Safety Assessment by a qualified assessor (a toxicologist or cosmetic chemist with the appropriate qualifications) and a Product Information File.
In the UK post-Brexit, the Cosmetics Regulation (EU) No 1223/2009 has been retained in domestic law. The same concentration guidance applies, and products must be notified through the UK's Office for Product Safety and Standards (OPSS) portal, with a UK Responsible Person designated.
In Canada, kojic acid is permitted as a cosmetic ingredient. Manufacturers must submit a Cosmetic Notification Form (CNF) to Health Canada within 10 days of first sale. If any skin-lightening claims are made, Health Canada may scrutinize the product more closely under its drug-cosmetic borderline policy.
Transexamic acid has a cleaner regulatory profile across most markets. It is permitted at cosmetic-grade concentrations in the US, EU, UK, Canada, and most ASEAN markets without specific concentration restrictions in leave-on cosmetics as of current guidance.
The critical compliance risk area is claims language. Phrases like "eliminates dark spots," "corrects hyperpigmentation," or "treats melasma" can be interpreted as drug claims by regulators in multiple markets, which would reclassify your product and require a completely different approval pathway. Work with a cosmetic regulatory consultant to develop compliant claims such as "visibly brightens the appearance of uneven skin tone" before your artwork is finalized.
Ingredients in this answer: Kojic Acid
Read the full guide on Private Label Tranexamic & Kojic Acid Body Lotion Low MOQ →